-
公开(公告)号：US20230071749A1
公开(公告)日：2023-03-09
申请号：US17932117
申请日：2022-09-14
Applicant: Janssen Biotech, Inc.
Inventor： Steven Jacobs , Karyn O'Neil
Abstract: A protein scaffold based on a consensus sequence of fibronectin type III (FN3) proteins, such as the tenth FN3 repeat from human fibronectin (human Tenascin), including isolated nucleic acids that encode a protein scaffold, vectors, host cells, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices. In particular, protein scaffold molecules binding to IgG have been identified as useful for diagnostic and/or therapeutic applications.
-
公开(公告)号：US10954284B2
公开(公告)日：2021-03-23
申请号：US15637276
申请日：2017-06-29
Applicant: Janssen Biotech, Inc.
Inventor： Mark Anderson , Ricardo Attar , Michael Diem , Linus Hyun , Steven Jacobs , Alastair King , Donna Klein , Sheri Moores , Karyn O'Neil , Kristen Picha
Abstract: Monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making thereof are useful in the generation of therapeutic molecules and treatment and diagnosis of diseases and disorders.
-
公开(公告)号：US20170362301A1
公开(公告)日：2017-12-21
申请号：US15629090
申请日：2017-06-21
Applicant: Janssen Biotech, Inc.
Inventor： Mark Anderson , Ricardo Attar , Michael Diem , Linus Hyun , Alastair King , Steven Jacobs , Shalom Goldberg , Donna Klein , Sheri Moores , Karyn O'Neil , Kristen Picha
IPC: C07K14/78
Abstract: Cysteine engineered monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules comprising one or more free cysteine amino acids are prepared by mutagenizing a nucleic acid sequence of a parent molecule and replacing one or more amino acid residues by cysteine to encode the cysteine engineered FN3 domain containing monospecific or bispecific molecules; expressing the cysteine engineered FN3 domain containing molecules; and recovering the cysteine engineered FN3 domain containing molecule. Isolated cysteine engineered monospecific or bispecific FN3 domain containing molecules may be covalently attached to a detection label or a drug moiety and used therapeutically.
-
公开(公告)号：US20170305997A1
公开(公告)日：2017-10-26
申请号：US15637276
申请日：2017-06-29
Applicant: Janssen Biotech, Inc.
Inventor： Mark Anderson , Ricardo Attar , Michael Diem , Linus Hyun , Steven Jacobs , Alastair King , Donna Klein , Sheri Moores , Karyn O'Neil , Kristen Picha
CPC classification number: C07K14/78 , A61K38/00 , A61K45/06 , A61K2039/505 , C07K14/47 , C07K14/705 , C07K14/71 , C07K16/28 , C07K16/2863 , C07K2317/31 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C07K2318/20 , C07K2319/70
Abstract: Monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making thereof are useful in the generation of therapeutic molecules and treatment and diagnosis of diseases and disorders.
-
公开(公告)号：US20240100129A1
公开(公告)日：2024-03-28
申请号：US18496397
申请日：2023-10-27
Applicant: Janssen Biotech, Inc.
Inventor： Michael Diem , Steven Jacobs , Karyn O'Neil , Thomas Rutkoski
CPC classification number: A61K38/39 , A61K47/549 , C07K14/78 , C07K16/18 , C07K16/40 , G01N33/68 , A61K2039/505 , C07K2317/94
Abstract: Fibronectin type III domains (FN3) that specifically bind to serum albumin, related polynucleotides capable of encoding serum albumin-specific FN3 domains, cells expressing the FN3 domains, as well as associated vectors, detectably labeled FN3 domains and FN3 domains fused to a heterologous moiety are useful in extending the half-life of molecules in diagnostic and therapeutic applications.
-
Patent Agency Ranking
公开(公告)号：US11702475B2
公开(公告)日：2023-07-18
申请号：US17303425
申请日：2021-05-28
Applicant: Janssen Biotech, Inc.
Inventor： Shalom Goldberg , Steven Jacobs , Tricia Lin , Karyn O'Neil
CPC classification number: C07K16/2863 , C07K14/78 , G01N33/74 , A61K2039/505 , C07K2317/31 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C07K2318/20 , C07K2319/00 , C07K2319/30 , C07K2319/31
Abstract: Cysteine engineered monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules comprising one or more free cysteine amino acids are prepared by mutagenizing a nucleic acid sequence of a parent molecule and replacing one or more amino acid residues by cysteine to encode the cysteine engineered FN3 domain containing monospecific or bispecific molecules; expressing the cysteine engineered FN3 domain containing molecules; and recovering the cysteine engineered FN3 domain containing molecule. Isolated cysteine engineered monospecific or bispecific FN3 domain containing molecules may be covalently attached to a detection label or a drug moiety and used therapeutically.
-
公开(公告)号：US20210228688A1
公开(公告)日：2021-07-29
申请号：US17153229
申请日：2021-01-20
Applicant: Janssen Biotech, Inc.
Inventor： Michael Diem , Steven Jacobs , Karyn O'Neil , Thomas Rutkoski
Abstract: Fibronectin type III domains (FN3) that specifically bind to serum albumin, related polynucleotides capable of encoding serum albumin-specific FN3 domains, cells expressing the FN3 domains, as well as associated vectors, detectably labeled FN3 domains and FN3 domains fused to a heterologous moiety are useful in extending the half-life of molecules in diagnostic and therapeutic applications.
-
公开(公告)号：US11072663B2
公开(公告)日：2021-07-27
申请号：US16227597
申请日：2018-12-20
Applicant: Janssen Biotech, Inc.
Inventor： Shalom Goldberg , Steven Jacobs , Tricia Lin , Karyn O'Neil
Abstract: Cysteine engineered monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules comprising one or more free cysteine amino acids are prepared by mutagenizing a nucleic acid sequence of a parent molecule and replacing one or more amino acid residues by cysteine to encode the cysteine engineered FN3 domain containing monospecific or bispecific molecules; expressing the cysteine engineered FN3 domain containing molecules; and recovering the cysteine engineered FN3 domain containing molecule. Isolated cysteine engineered monospecific or bispecific FN3 domain containing molecules may be covalently attached to a detection label or a drug moiety and used therapeutically.
-
公开(公告)号：US10925932B2
公开(公告)日：2021-02-23
申请号：US15611296
申请日：2017-06-01
Applicant: Janssen Biotech, Inc.
Inventor： Michael Diem , Steven Jacobs , Karyn O'Neil , Thomas Rutkoski
Abstract: Fibronectin type III domains (FN3) that specifically bind to serum albumin, related polynucleotides capable of encoding serum albumin-specific FN3 domains, cells expressing the FN3 domains, as well as associated vectors, detectably labeled FN3 domains and FN3 domains fused to a heterologous moiety are useful in extending the half-life of molecules in diagnostic and therapeutic applications.
-
公开(公告)号：US20200325210A1
公开(公告)日：2020-10-15
申请号：US16840479
申请日：2020-04-06
Applicant: Janssen Biotech, Inc.
Inventor： Mark Anderson , Ricardo Attar , Michael Diem , Shalom Goldberg , Linus Hyun , Steven Jacobs , Alastair King , Donna Klein , Sheri Moores , Karyn O'Neil , Kristen Picha
Abstract: Cysteine engineered monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules comprising one or more free cysteine amino acids are prepared by mutagenizing a nucleic acid sequence of a parent molecule and replacing one or more amino acid residues by cysteine to encode the cysteine engineered FN3 domain containing monospecific or bispecific molecules; expressing the cysteine engineered FN3 domain containing molecules; and recovering the cysteine engineered FN3 domain containing molecule. Isolated cysteine engineered monospecific or bispecific FN3 domain containing molecules may be covalently attached to a detection label or a drug moiety and used therapeutically.
-
-
-
-
-
-
-
-
-
Search Results
35
records
(took 0.025 seconds)
